Lantheus to Acquire Evergreen Theragnostics for Up to $1 Billion
January 29, 2025
January 29, 2025
NEW YORK, Jan. 29 -- Cooley, a law firm, issued the following news release:
Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics.
Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and up to $752.5 million in development . . .
Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics.
Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and up to $752.5 million in development . . .